论文部分内容阅读
目的：探讨血清可溶性细胞间粘附分子－１（ｓＩＣＡＭ－１）和透明质酸（ＨＡ）与肝纤维化及肝损害的关系。方法：用ＥＬＩＳＡ法检测正常人、慢性肝炎肝硬化患者血清ｓＩＣＡＭ－１。用ＲＩＡ法测定正常人、慢性肝炎肝硬化患者血清ＨＡ。结果：慢性肝病患者各组血清ｓＩＣＡＭ－１均显著高于正常人，各组间存在显著差异；血清ＨＡ水平在慢性肝炎中度组、重度组、肝硬化组明显高于正常人。在不同临床类型的慢性肝病患者中ＨＡ血清水平也存在显著差异，病情越重，血清ｓＩＣＡＭ－１和ＨＡ水平越高。两者与血清草酰乙酸转氨酶（ＡＳＴ）、总胆红素、球蛋白呈显著正相关，与血清白蛋白呈显著负相关。结论：慢性肝病患者血清ｓＩＣＡＭ－１和血清ＨＡ可作为判断肝纤维化及肝损伤程度的指标。
Objective: To investigate the relationship between serum soluble intercellular adhesion molecule-1 (sICAM-1) and hyaluronic acid (HA) and hepatic fibrosis and liver damage. Methods: Serum sICAM-1 levels in patients with chronic hepatitis and cirrhosis were detected by ELISA. Determination of serum HA in patients with normal liver cirrhosis by RIA method. Results: The serum levels of sICAM-1 in patients with chronic liver disease were significantly higher than those in normal people, and there was significant difference among the groups. The level of serum HA in patients with chronic liver disease was significantly higher than that in moderate, severe and cirrhosis patients. In different clinical types of patients with chronic liver disease serum levels of HA are also significantly different, the more serious the disease, serum sICAM-1 and HA levels higher. Both of them had significant positive correlation with serum oxaloacetate aminotransferase (AST), total bilirubin and globulin, and negatively correlated with serum albumin. Conclusion: Serum sICAM-1 and serum HA in patients with chronic liver disease can be used as indicators to determine the degree of hepatic fibrosis and liver injury.